title: Weight Gain While Switching from Polypharmacy to Ziprasidone: A Case Report.
abstract: Second-generation antipsychotics (SGAs), valproate, and sulpiride are related to significant weight gain and risk of metabolic syndrome (MetS). Among SGAs, olanzapine and clozapine are associated with the highest metabolic risk while ziprasidone is among one of the SGAs with the lowest risk. Several reports suggest that weight loss is observed in switching other antipsychotics to ziprasidone. Here we describe a female patient with chronic paranoid schizophrenia who had an unexpected weight gain and developed MetS during a cross-switch from a polypharmacy of olanzapine, valproate and sulpiride to ziprasidone monotherapy.
authors: Chin-Pang
authors: CP
authors: Lee
authors: Alice Pei-Jung
authors: AP
authors: Chen
authors: Yeong-Yuh
authors: YY
authors: Juang
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D024821:Metabolic Syndrome / Q000139:chemically induced*; D010879:Piperazines / Q000009:adverse effects*; D019338:Polypharmacy; D012563:Schizophrenia, Paranoid / Q000188:drug therapy*; D013844:Thiazoles / Q000009:adverse effects*; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; C092292:ziprasidone
keywords: Polypharmacy; Schizophrenia; Weight Gain; Ziprasidone